Senti Bio to Participate in Upcoming Investor Conferences Senti Bio will participate in two upcoming investor conferences in September.

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights – Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.

Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by...

Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...